Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - OncoMed Pharmaceuticals Inc | d344523ds1a.htm |
| EX-5.1 - EX-5.1 - OncoMed Pharmaceuticals Inc | d344523dex51.htm |
| EX-1.1 - EX-1.1 - OncoMed Pharmaceuticals Inc | d344523dex11.htm |
| EX-10.7 - EX-10.7 - OncoMed Pharmaceuticals Inc | d344523dex107.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 2, 2013 (except as to the last paragraph of Note 2, as to which the date is July X, 2013), in Amendment No. 9 to the Registration Statement (Form S-1 No. 333-181331) and related Prospectus of OncoMed Pharmaceuticals, Inc. for the registration of shares of its common stock.
Ernst & Young LLP
Redwood City, California
The foregoing consent is the form that will be signed upon the effectiveness of the reverse stock split as described in the last paragraph of Note 2 to the financial statements.
/s/ Ernst & Young LLP
Redwood City, California
July 8, 2013